戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  frequently with lopinavir-ritonavir, mainly gastrointestinal disturbance.
2 ith off-target effects, including nausea and gastrointestinal disturbance.
3 icities, peripheral neuropathy, fatigue, and gastrointestinal disturbances.
4  MMF for infection, myelosuppression, and/or gastrointestinal disturbances.
5  MMF for infection, myelosuppression, and/or gastrointestinal disturbances.
6 to further unravel the nature of the chronic gastrointestinal disturbances.
7 tanding of how sleep disturbances arise from gastrointestinal disturbances.
8 hrombotic episodes (7%), bone pain (5%), and gastrointestinal disturbance (4%).
9 most common drug-related adverse events were gastrointestinal disturbances and increased serum creati
10                                           As gastrointestinal disturbances are common in children wit
11 heral artery disease (nilotinib, ponatinib), gastrointestinal disturbance (bosutinib), or increased a
12 ctors of infection is their association with gastrointestinal disturbances, but this relationship to
13 n in distal extremities including joints and gastrointestinal disturbances, but was absent from an as
14  anemia, 14%; and thrombocytopenia, 23%) and gastrointestinal disturbances (diarrhea, any grade, 72%;
15                                    Sleep and gastrointestinal disturbances have also been frequently
16 ers seeking medical care have a diagnosis of gastrointestinal disturbance in approximately one-third
17 and impaired gut motility) that explains the gastrointestinal disturbances in patients with FOXP1 syn
18                                              Gastrointestinal disturbances in PD patients, along with
19 he cause of chronic unexplained diarrhea and gastrointestinal disturbances in transplant patients.
20 ourse involved recurrent febrile illness and gastrointestinal disturbance, lacking an infective cause
21 effects, including anemia, thrombocytopenia, gastrointestinal disturbances, metabolic abnormalities,
22 production (montelukast, n=6; placebo, n=2), gastrointestinal disturbance (montelukast, n=3; placebo,
23 t short shedding events were often linked to gastrointestinal disturbances, our results help explain
24 protease inhibitors currently in use include gastrointestinal disturbances, paraesthesias, hyperbilir
25 sistant organisms and can lead to persistent gastrointestinal disturbance post-travel.
26                               These included gastrointestinal disturbance (present in 9); edema (9);
27 ity with azathioprine (five [15%] of 34) and gastrointestinal disturbances (seven [15%] of 48) with m
28 imal performance included these factors plus gastrointestinal disturbance, severe neutropenia, and pr
29 such as bulbar dysfunction, hearing loss and gastrointestinal disturbance should help prioritize gene
30                          Ten trials reported gastrointestinal disturbances, such as nausea, vomiting,
31  frequent dosing schedules or elimination of gastrointestinal disturbances, the most common adverse e
32                                              Gastrointestinal disturbance was more common among patie
33               Sensorineural hearing loss and gastrointestinal disturbance were also important finding
34                                        Minor gastrointestinal disturbances were more commonly reporte